# KEAPSAKE (NCT04265534)

> KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

No report yet. It can be ordered.

- Drugs tested: telaglenastat
- Indication: first-line metastatic KEAP1/NRF2-mutated nonsquamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04265534
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Calithera Biosciences, Inc
- Conditions: Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung; KEAP1 Gene Mutation; NRF2 Gene Mutation; NFE2L2 Gene Mutation
- Interventions: Telaglenastat; Carboplatin Chemotherapy; Pemetrexed Chemotherapy; Pembrolizumab Immunotherapy; Placebo; Folic acid 400 -1000 μg; Vitamin B12 1000 μg; Dexamethasone 4 mg
- Enrollment: 40
- Primary outcome: Progression-Free Survival (PFS), Assessed by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Primary outcome: Safety and Tolerability of Telaglenastat Plus Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Type, Incidence, Severity, Seriousness, and Study Drug Relatedness of Adverse Events per CTCAE v5.0
- Primary outcome: Recommended Phase 2 Dose of Telaglenastat in Combination with Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Incidence and Nature of Protocol Defined Dose-Limiting Toxicities (DLTs) During the Safety Run-in Period

## Indexed commentary on KEAPSAKE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keapsake-nct04265534